The integrated stress response is tumorigenic and constitutes a therapeutic liability in KRAS-driven lung cancer
The Integrated Stress Response (ISR) is a cytoprotective pathway upregulated in many cancers. Here the authors show that the activation of PERK/p-eIF2α arm of ISR enhances ERK phosphorylation through translation repression of DUSP6, thus resulting in KRAS-driven lung tumorigenesis.
Main Authors: | Nour Ghaddar, Shuo Wang, Bethany Woodvine, Jothilatha Krishnamoorthy, Vincent van Hoef, Cedric Darini, Urszula Kazimierczak, Nicolas Ah-son, Helmuth Popper, Myriam Johnson, Leah Officer, Ana Teodósio, Massimo Broggini, Koren K. Mann, Maria Hatzoglou, Ivan Topisirovic, Ola Larsson, John Le Quesne, Antonis E. Koromilas |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2021-07-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-021-24661-0 |
Similar Items
-
The Integrated Stress Response Is Tumorigenic and Constitutes a Therapeutic Liability in Somatotroph Adenomas
by: Zhenye Li, et al.
Published: (2022-10-01) -
USP5-Beclin 1 axis overrides p53-dependent senescence and drives Kras-induced tumorigenicity
by: Juan Li, et al.
Published: (2022-12-01) -
Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity
by: Hema Adhikari, et al.
Published: (2021-09-01) -
Rapamycin response in tumorigenic and non-tumorigenic hepatic cell lines.
by: Rosa H Jimenez, et al.
Published: (2009-10-01) -
Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS‐mutant cancer
by: Zhang Yang, et al.
Published: (2021-09-01)